Genotypic and haplotype analysis of SOCS3 gene polymorphisms (rs4969169, rs12953258, rs1061489) in association with clinicopathological factors in breast cancer Authors: Raviteja Reddy Alipeddi, Chiranjeevi Padala, Kaushik Puranam, Kayalvili Ulaganathan, Rani Durga Neeharika, Pallavi Sampanmudumby, Sanjeeva kumari Chinta, Surekha Rani Hanumanth Published: 2025 ABSTRACT AbstractBackgroundBreast cancer (BC) is the most common malignancy diagnosed among women worldwide. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway plays a critical role in regulating cellular differentiation, maturation, proliferation, and apoptosis across various cell types involved in cancer initiation and progression. The suppressor of cytokine signaling 3 (SOCS3) acts as a key negative regulator of the JAK/STAT pathway. Therefore, investigating the role of single nucleotide polymorphisms (SNPs) in the SOCS3 gene is essential to better understand their contribution to the pathogenesis of breast cancer.MethodsThis case–control study included 300 female patients with breast cancer and 300 healthy female volunteers as controls. Ethical approval was obtained from the Institutional Ethics Committee prior to the commencement of study and was in compliance with the Helsinki Declaration. Written informed consent was obtained from all participants. Three SOCS3 SNPs—rs4969169 (C > T), rs12953258 (C > A), and rs1061489 (G > A)—were genotyped using Polymerase chain reaction-Restriction fragment length Polymorphism and Amplification refractory mutation system-PCR methods. Genotypic distributions, allele frequencies, and haplotype associations were analyzed, with statistical significance set at p < 0.05.ResultsThe TT genotype and T allele of rs4969169 (C > T) conferred 4.29-fold and 2.16-fold increased risk, respectively, for breast cancer. Similarly, the CA genotype and A allele of rs12953258 (C > A) were associated with 1.95-fold and 2.02-fold increased risk, while the GA genotype and A allele of rs1061489 (G > A) conferred 4.58-fold and 3.87-fold increased risk, respectively. Haplotype analysis revealed significant associations with advanced disease stage, lymph node involvement, lobular carcinoma, and negative receptor status for ER, PR, and HER2/neu. The T–C–G, C–A–G, C–C–A, and T–C–A haplotypes conferred 2.18-, 2.64-, 3.65-, and 13.66-fold increased risk, respectively, for breast cancer development.ConclusionTherefore, our study results suggest the significance of genotypic and haplotype analysis of SOCS3 gene polymorphisms and its impact on progression and risk prediction of breast cancer.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12920-025-02284-4.Keywords: Breast cancer, PCR-RFLP, ARMS-PCR, Single nucleotide polymorphisms, SOCS3 Introduction Cancer is a group of diseases characterized by uncontrollable cell division and infiltration [1]. Breast carcinoma is the most prevalent cancer diagnosed among women worldwide. Every year, approximately 2.3 million women are diagnosed with BC with an estimated 684,996 deaths. BC accounts for about 11.7% of all cancer cases globally, ranking as the second most common cancer overall [2, 3]. It is a leading cause of cancer incidence and mortality in India, accounting 13.5% of new cancer cases and 10% of cancer-related deaths. It is now the most common type of cancer among women globally, and it is spreading at a rapid pace in India. Breast tumor progression involves interactions between tumor cells and various components of the tumor microenvironment, including immune cells (B cells, T cells, mast cells and macrophages), fibroblasts, myofibroblasts and extracellular matrix. Immune cells play a role in secreting cytokines, growth factors and adhesion molecules that support advancement of cancer cells through signaling pathways and creating ideal growth environments. The development of breast carcinoma is influenced by various genetic, epigenetic, environmental and lifestyle factors which are closely linked to specific tumor subtypes categorized by hormone receptor status and other characteristics in breast cancer and lymph node involvement is associated with a higher recurrence rate, distant organ metastasis and significantly poorer prognosis [2, 4–6]. Cytokine-induced signaling pathways are tightly regulated by several mechanisms, including activation phosphatases, increasing proteins that block STAT binding to DNA, and producing suppressors of the cytokine signaling (SOCS) proteins that inhibit JAK activity, hinder STAT recruitment to the receptor and promote substrate breakdown. SOCS dysregulation may lead to the development of inflammatory conditions, increased susceptibility to infectious diseases and other pathologies as well as an increased propensity of cancer development [7, 8]. The JAK-STAT pathway is a series of protein interactions within cells that play a role in immunity, cell division, apoptosis, and oncogenesis. The pathway transmits information from chemical signals external to a cell to the cell nucleus, leading to gene activation via transcription process [9, 10]. The family of intracellular proteins, known as SOCS proteins, consists of eight members that regulate signaling triggered by cytokines and the activation status of cells. SOCS family comprises SOCS 1 to SOCS 7 and CIS. SOCS3 is one of the SOCS protein family and has numerous gene polymorphisms at different loci, located on the chromosome region 17q24-17q25 [11]. The consequences of dysregulation of JAK/STAT signaling have been implicated in the oncogenesis of multiple tumor types. SOCS3 acts as a negative regulatory protein of JAK/STAT pathway which might play crucial role in initiation and progression of cancer [12]. In addition, contemporary studies have identified SOCS3 SNPs in the promoter, exon, intron and 3’UTR regions have been associated with various diseases like hepatocellular carcinoma, infantile asthma, gastric cancer, obesity etc [13]. Even though a close association of SOCS3 and breast cancer was established, the influence of SOCS3 gene polymorphisms on the breast cancer pathogenesis and prognosis remains scanty. Therefore, our study aimed to evaluate the association between SOCS3 gene polymorphisms and breast carcinoma in a South Indian population, and to explore population-specific genotypic (SOCS3) and phenotypic correlations in a case control study setting on BC patients. The present study is first of its kind to focus on the SOCS3 gene polymorphisms (rs4969169 C > T, rs12953258 C > A and rs1061489 G > A) in relation with clinicopathological status for susceptibility and progression of BC. Materials and methods Study design and participants The present study is approved by institutional and hospital ethical Review boards with (Approval number 10/EC/NEW/INST/2023/4032). The study included 300 women breast carcinoma patients and 300 healthy women control subjects after obtaining informed written consent. The BC patients were recruited from MNJ Institute of Oncology and Regional Cancer Center, Hyderabad. The histo-clinicopathological information of the BC patients was obtained from the hospital medical records.. Inclusion criteria Histopathologically diagnosed breast cancer individuals who have been registered in MNJ Institute of Oncology and Regional Cancer Centre were recruited as breast cancer subjects. Healthy individuals with no medical history of any cancer were recruited as controls. Exclusion criteria Individuals with medical history of benign tumors, papillary carcinoma or any other type of cancer were excluded from the study. Polymorphisms and genotyping analysis A 5mL sample of peripheral venous blood was collected from each subject in EDTA-coated tubes. Samples were processed within two hours of collection. Genomic DNA was extracted from peripheral whole blood using the Bioserve DNA Blood Mini kit following the manufacturer’s protocol [14]. DNA purity and concentration were assessed by Nanodrop spectrophotometry (A260/280 ratio = 1.8–2.0), and integrity was verified through 1% agarose gel electrophoresis. The genotypes of SOCS3 gene rs4969169 C >T, rs12953258 C >A and rs1061489 G >A polymorphisms were determined using PCR-RFLP (Polymerase chain reaction- Restriction fragment length Polymorphism) and ARMS-PCR (Amplification refractory mutation system-PCR) methods respectively. Primer sequences, size of the PCR products (in base pair), Restriction enzymes used and PCR conditions are shown in Table 1. For genotyping quality assessment purposes, we randomly selected and repeated 10% of samples. The samples were found to be 100% concordant in two independent assays. Table 1Primer sequences and PCR conditions for genotyping analysis of SOCS3 gene polymorphismsSNP IDPrimer sequencesAnnealing Temperature(in OC)PCR methodAmplicon Size / Restriction Enzyme (RE)Genotype and Band Pattern(bp)rs4969169C > TFP: GGGACAGGGAGCATTTAAGGRP: GGGAATCTTCAAACTTTCCAACGG58.0PCR-RFLP547 bp(KpnI)CC − 547 bp.TT − 311, 236 bp.CT − 547, 311, 236 bp.rs12953258C > AOF: 5’ CCGCGCTCAGCCTTTCTCTGCTGCGA 3’OR: 5’AGTCCACAAAGGAGCCTTCGCGCGCG 3’IF: 5’ CCCGCACGCAGCCAGCCGTCC 3’IR: 5’ AGCTGGGCCGGGCGGGCGACT 3’63.0ARMS-PCR338 bp211 bp170 bpAA – 338, 211 bpCC – 338, 170 bpCA – 338,211, 170 bp.rs1061489G > AFP: GTCTGGGACCAAGAACCTG RP: GCCCCCGGAGTAGATGTAA61.7PCR-RFLP252 bp(ApaLI)GG-110, 143 bpAA- 253 bpGA- 110, 143, 253 bpFP Forward Primer, RP Reverse Primer, OF Outer Forward, OR Outer Reverse, IF Inner Forward, IR Inner Reverse. bp base pairs, RE Restriction Enzyme used in PCR-RFLP, PCR-RFLP Polymerase Chain Reaction–Restriction Fragment Length Polymorphism, ARMS PCR Amplification Refractory Mutation System PCR Primer sequences and PCR conditions for genotyping analysis of SOCS3 gene polymorphisms rs4969169 C > T FP: GGGACAGGGAGCATTTAAGG RP: GGGAATCTTCAAACTTTCCAACGG 547 bp (KpnI) CC − 547 bp. TT − 311, 236 bp. CT − 547, 311, 236 bp. rs12953258 C > A OF: 5’ CCGCGCTCAGCCTTTCTCTGCTGCGA 3’ OR: 5’AGTCCACAAAGGAGCCTTCGCGCGCG 3’ IF: 5’ CCCGCACGCAGCCAGCCGTCC 3’ IR: 5’ AGCTGGGCCGGGCGGGCGACT 3’ 338 bp 211 bp 170 bp AA – 338, 211 bp CC – 338, 170 bp CA – 338,211, 170 bp. rs1061489 G > A 252 bp (ApaLI) GG-110, 143 bp AA- 253 bp GA- 110, 143, 253 bp FP Forward Primer, RP Reverse Primer, OF Outer Forward, OR Outer Reverse, IF Inner Forward, IR Inner Reverse. bp base pairs, RE Restriction Enzyme used in PCR-RFLP, PCR-RFLP Polymerase Chain Reaction–Restriction Fragment Length Polymorphism, ARMS PCR Amplification Refractory Mutation System PCR Statistical analyses Genotype and allele frequency distribution data of the genetic polymorphisms under study were determined, deviations from Hardy–Weinberg equilibrium (HWE) were tested using chi-square statistics. Associations between SOCS3 genotypes and BC risk were estimated by odds ratios (OR) and 95% confidence intervals (CI) using binary logistic regression. The p-values were two-sided, and p < 0.05 was considered to be statistically significant. The present study also employed different other statistical tools to analyse both qualitative and quantitative variables, which include SNPStats [14, 15], IBM SPSS (Version 20.0) and Graphpad Prism (Version 8) [14, 16]. Insilico analyses The SNP in upstream promoter region of SOCS3 was analyzed for the presence or absence of sites for binding of transcription factors using AliBaba2.1 tool (https://www.gene-regulation.com/pub/programs/alibaba2/index.html) [17]. The secondary structures of mRNA for SOCS3 SNPs were identified by the RNA SNP WebServer (https://rth.dk/resources/rnasnp/about.php) and ViennaRNA WebServer http://rna.tbi.univie.ac.at [18, 19]. Results Comparison of demographic characteristics between breast carcinoma patients and controls The basic demographic characteristics of BC patients and healthy controls are shown in Table 2. In current study, age of the BC patients is in the range of 30–75 years, and their average age at BC diagnosis was 47.98 years (SD ± 10.80). Our data revealed that 37% of breast cancer patients had a higher BMI (> 25 kg/m2). About 62.7% and 37.3% of BC patients were living in rural and urban areas respectively. Consumption of mixed diet was found to be 85.6% and 71% in cases and controls respectively. Table 2Demographic characteristics of study subjectsCharacteristicsHealthy Controls(N = 300) N (%)BC Cases(N = 300) N (%)P ValueAge (Y)46.34 ± 7.9747.98 ± 10.80 < 0.0001BMINormal (18.5–24.9. (kg/m2)Obese (> 25 (kg/m2)253 (84.33)47 (15.67)189 (63.0)111 (37.0) < 0.0001Area of LivingRuralUrban171 (57.0)129 (43.0)188 (62.7)112 (37.3)0.18DietVegetariansNon-vegetarians87 (29.0)213 (71.0)43 (14.3)257 (85.7) < 0.0001SmokingNon-SmokersSmokers273 (91.0)27 (9.0)245 (81.7)55 (18.3) < 0.001Alcohol consumptionNon-AlcoholicsAlcoholics243 (81.0)57 (19.0)179 (59.6)121 (40.4) < 0.0001Data are presented as mean ± standard deviation (SD) or number (percentage)BMI Body Mass Index, BC Breast Cancer. P values were calculated using the independent t-test for continuous variables (age) and the chi-square (χ²) test for categorical variables. A p value < 0.05 was considered statistically significant. The present study revealed that the risk factors like Age, BMI, Diet, habit of smoking and alcohol consumption were found to be associated with Breast Cancer patients Demographic characteristics of study subjects Normal (18.5–24.9. (kg/m2) Obese (> 25 (kg/m2) 253 (84.33) 47 (15.67) 189 (63.0) 111 (37.0) Rural Urban 171 (57.0) 129 (43.0) 188 (62.7) 112 (37.3) Vegetarians Non-vegetarians 87 (29.0) 213 (71.0) 43 (14.3) 257 (85.7) Non-Smokers Smokers 273 (91.0) 27 (9.0) 245 (81.7) 55 (18.3) Non-Alcoholics Alcoholics 243 (81.0) 57 (19.0) 179 (59.6) 121 (40.4) Data are presented as mean ± standard deviation (SD) or number (percentage) BMI Body Mass Index, BC Breast Cancer. P values were calculated using the independent t-test for continuous variables (age) and the chi-square (χ²) test for categorical variables. A p value < 0.05 was considered statistically significant. The present study revealed that the risk factors like Age, BMI, Diet, habit of smoking and alcohol consumption were found to be associated with Breast Cancer patients In our study, a greater number of breast cancer patients (18.3%) exhibited tobacco intake habit compared to controls (9%). We have also observed that the frequency of alcoholics among BC patients (40.4%) was higher than that of the controls (19%). In the present study, we have also observed that 57% of patients presented with breast cancer had middle stage menarche, 16% of the patients had early-stage menarche and 27% had later stage menarche. The mean age at menarche of breast carcinoma patients and controls was 13.07 ± 1.13 years and 14.01 ± 1.61 years, respectively. About 21% of Breast cancer patients reported irregular menstruation cycles. Nulliparity was more frequent among breast cancer patients, occurring in 8.7% of cases compared to 2% in controls. Parental consanguinity history was more prominent in breast carcinoma patients (37%), when compared to controls (12.3%). Approximately 15.3% cases of BC are associated with a family history as shown in Table 3. Table 3Baseline reproductive and family history characteristics of study subjectsCharacteristicsHealthy Control (N = 300) N (%)BC Cases(N = 300) N (%)P Value Reproductive History Age at menarche14.01 ± 1.6113.07 ± 1.13 < 0.0001Menstrual cyclesRegularIrregular247 (82.3)53 (17.7)236 (79.0)64 (21.0)0.30Menstruation StatusPre-menopausalPost-menopausal156 (52.0)144 (48.0)176 (59.0)124 (41.0)0.1ParityParousNulliparous294 (98.0)6 (2.0)274 (91.3)26 (8.7) < 0.0005LactationYesNo286 (97.3)8 (2.7)249 (91.0)25 (9.0) 0.002 Family History Parental ConsanguinityNon-ConsanguineousConsanguineous263 (87.7)37 (12.3)188 (63.0)112 (37.0) < 0.0001Data are presented as mean ± standard deviation (SD) or number (percentage)BC Breast Cancer. P values were calculated using the independent t-test for continuous variables (e.g., age at menarche) and the chi-square (χ²) test for categorical variables. A p value < 0.05 was considered statistically significant. The present study revealed that the risk factors like Age at menarche, Nulliparity, no lactation and Consanguinity were found to be associated with Breast Cancer patients Baseline reproductive and family history characteristics of study subjects Regular Irregular 247 (82.3) 53 (17.7) 236 (79.0) 64 (21.0) Pre-menopausal Post-menopausal 156 (52.0) 144 (48.0) 176 (59.0) 124 (41.0) Parous Nulliparous 294 (98.0) 6 (2.0) 274 (91.3) 26 (8.7) Yes No 286 (97.3) 8 (2.7) 249 (91.0) 25 (9.0) Non-Consanguineous Consanguineous 263 (87.7) 37 (12.3) 188 (63.0) 112 (37.0) Data are presented as mean ± standard deviation (SD) or number (percentage) BC Breast Cancer. P values were calculated using the independent t-test for continuous variables (e.g., age at menarche) and the chi-square (χ²) test for categorical variables. A p value < 0.05 was considered statistically significant. The present study revealed that the risk factors like Age at menarche, Nulliparity, no lactation and Consanguinity were found to be associated with Breast Cancer patients With respect to clinicopathological characteristics of breast carcinoma patients, we have observed that most of the patients were in the early stage (T0-T2; 65.7%) followed by the late stage (T3-T4; 34.3%) at diagnosis based on TNM classification (8th edition of the AJCC TNM Classification). Further, based on medical records, large tumors (> 50 mm) and distant metastasis were observed in 34.3% of patients, while 73.3% had lymph node involvement. The data analysis pertaining to hormonal status has revealed that 177 (59%) and 168 (56%) of BC patients showed positive expression of estrogen receptor (ER) and progesterone receptor (PR) respectively. HER2/neu receptor status was found to be positive among 163 (54.3%). Of the total patients, 64 (21.4%) had triple negative status as shown in Table 4. Table 4Baseline clinicopathological characteristics of BC patientsCharacteristicsBC Cases [N = 300]N (%)Stage of the cancerEarly stage (T0-T2)Late stage (T3-T4)197 (65.7)103 (34.3)Size of Tumor< 50 mm> 50 mm197 (65.7)103 (34.3)Histological subtypeDuctalLobular247 (82.3)53 (17.7)Axillary Lymph nodal statusNegativePositive80 (26.7)220 (73.3)ER statusPositiveNegative177 (59)123 (41)PR statusPositiveNegative168 (56)132 (44)HER2/neu receptor statusPositiveNegative163 (54.3)111 (37)Triple Receptor statusOther combinationsNegative239 (79.6)61 (21.4)MetastasisAbsentPresent197 (66.7)103 (34.3)ER Estrogen hormone receptor, PR Progesterone hormone receptor, HER2/neu Human epidermal growth factor receptor-2/neu Receptor Baseline clinicopathological characteristics of BC patients Early stage (T0-T2) Late stage (T3-T4) 197 (65.7) 103 (34.3) < 50 mm > 50 mm 197 (65.7) 103 (34.3) Ductal Lobular 247 (82.3) 53 (17.7) Negative Positive 80 (26.7) 220 (73.3) Positive Negative 177 (59) 123 (41) Positive Negative 168 (56) 132 (44) Positive Negative 163 (54.3) 111 (37) Other combinations Negative 239 (79.6) 61 (21.4) Absent Present 197 (66.7) 103 (34.3) ER Estrogen hormone receptor, PR Progesterone hormone receptor, HER2/neu Human epidermal growth factor receptor-2/neu Receptor Association analysis of alleles and genotypes with risk of breast cancer Genotype and allelic distribution of SOCS3 rs4969169 C > T and risk for BC The PCR-RFLP analysis of the SOCS3 rs4969169 C > T polymorphism generated three distinct genotypes (CC, CT, and TT) as illustrated in Fig. 1. The statistical analysis revealed that the CT genotype of SOCS3 (rs4969169 C > T) conferred a 2.06-folds risk, (OR = 2.06; 95% CI:1.38–3.07; p = 0.0001) and the TT genotype conferred 4.29 folds increased risk (OR = 4.29; 95% CI:1.39–13.17; p = 0.007) for the development of Breast carcinoma. Allele frequency distribution has shown that T allele was significantly associated with Breast cancer risk (OR = 2.16; 95% CI: 1.52–3.10, p < 0.001) as shown in Table 5. 3% agarose gel picture depicting 3 genotypes of SOCS3 rs4969169 by PCR-RFLP method Table 5Genotype and allele frequency distribution of SOCS3 polymorphism rs4969169 C > T in controls and BC patientsModelGenotypeHealthy Controls(N = 300)N (%)BC Cases(N = 300)N (%)OR (95% CI)P-valueCodominantC/C246 (82.0%)202 (67.3%)1.00 0.0001 0.007C/T50 (16.7%)83 (27.7%) 2.06 (1.38–3.07)T/T4 (1.3%)15 (5.0%) 4.29 (1.39–13.17)DominantC/C246 (82.0%)202 (67.3%)1.00 < 0.0001C/T-T/T54 (18.0%)98 (32.7%) 2.23 (1.52–3.27)RecessiveC/C-C/T296 (98.7%)285 (95.0%)1.000.012T/T4 (1.3%)15 (5.0%) 3.65 (1.19–11.19)Over dominantC/C-T/T250 (83.3%)217 (72.3%)1.00 0.0008C/T50 (16.7%)83 (27.7%) 1.96 (1.31–2.91)HWE---0.50.13 --- ---Allele frequencyCT542 (90.3)58 (9.7)487 (81.0)113 (19.0) 2.16 (1.52–3.10) < 0.001 Data are presented as number (percentage) BC Breast Cancer, OR Odds Ratio CI Confidence Interval, HWE Hardy–Weinberg EquilibriumP values were calculated using the chi-square (χ²) test or Fisher’s exact test, where appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression analysis. A p value < 0.05 was considered statistically significant Genotype and allele frequency distribution of SOCS3 polymorphism rs4969169 C > T in controls and BC patients 0.0001 0.007 C T 542 (90.3) 58 (9.7) 487 (81.0) 113 (19.0) Data are presented as number (percentage) BC Breast Cancer, OR Odds Ratio CI Confidence Interval, HWE Hardy–Weinberg Equilibrium P values were calculated using the chi-square (χ²) test or Fisher’s exact test, where appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression analysis. A p value < 0.05 was considered statistically significant Genotype and allelic distribution of SOCS3 rs12953258 C > A and risk for BC The ARMS-PCR analysis of SOCS3 rs12953258 C > A polymorphism yielded three distinct genotypes (CC, CA, and AA), as shown in Fig. 2. Statistical analysis of genotype frequencies revealed that the CA genotype of SOCS3 rs12953258 C > A conferred a 1.95-folds increased risk (OR = 1.95; 95% CI: 1.28–2.96; p = 0.0011) for the development of breast carcinoma. The allele frequency distribution further indicated that the A allele was significantly associated with Breast cancer risk (OR = 2.021; 95% CI:1.37-3.00, p < 0.001) as shown in Table 6. 3% agarose gel picture depicting 3 genotypes of SOCS3 rs12953258 C > A by Amplification refractory mutation system polymerase chain reaction (ARMS-PCR) method Table 6Genotype and allele frequency distribution of SOCS3 rs12953258 C > A polymorphism in BC patients and controlsModelGenotypeHealthy Controls(N = 300)N (%)BC Cases(N = 300)N (%)OR (95% CI)P-valueCodominantC/C255 (85.0%)220 (73.3%)1.00 0.00110.03C/A43 (14.3%)72 (24.0%) 1.95 (1.28–2.96)A/A2 (0.7%)8 (2.7%)4.52 (0.95–21.58)DominantC/C255 (85.0%)220 (73.3%)1.00 0.0004C/A-A/A45 (15.0%)80 (26.7%) 2.06 (1.37–3.10)RecessiveC/C-C/A298 (99.3%)292 (97.3%)1.000.053A/A2 (0.7%)8 (2.7%)3.98 (0.83–18.96)Over dominantC/C-A/A257 (85.7%)228 (76.0%)1.00 0.0025C/A43 (14.3%)72 (24.0%) 1.89 (1.24–2.88)HWE---0.70.49 --- ---Allele frequencyCA553 (92)47 (8)512 (85)88 (15) 2.02 (1.37-3.00) 0.00025Data are presented as number (percentage)BC Breast Cancer, OR Odds Ratio, CI Confidence Interval HWE Hardy–Weinberg Equilibrium. P values were calculated using the chi-square (χ²) test or Fisher’s exact test, where appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression analysis. A p value < 0.05 was considered statistically significant Genotype and allele frequency distribution of SOCS3 rs12953258 C > A polymorphism in BC patients and controls 0.0011 0.03 C A 553 (92) 47 (8) 512 (85) 88 (15) Data are presented as number (percentage) BC Breast Cancer, OR Odds Ratio, CI Confidence Interval HWE Hardy–Weinberg Equilibrium. P values were calculated using the chi-square (χ²) test or Fisher’s exact test, where appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression analysis. A p value < 0.05 was considered statistically significant Genotype and allelic distribution of SOCS3 rs1061489 G > A and risk for BC The PCR-RFLP analysis of the SOCS3 rs1061489 G > A polymorphism revealed three distinct genotypes (GG, GA, and AA), as illustrated in Fig. 3. The statistical analysis showed that the GA genotype of SOCS3 (rs1061489 G > A) conferred a 4.58-folds risk (OR = 4.58; 95% CI: 2.61–8.04; p = < 0.0001) for the development of Breast carcinoma. Allele frequency distribution has shown that A allele was significantly associated with breast carcinoma risk (OR = 3.87; 95% CI: 2.32–6.72, p < 0.001) as shown in Table 7. 3% agarose gel picture depicting 3 genotypes of SOCS3 rs1061489 G > A by PCR-RFLP method Table 7Genotype and allele frequency distribution of SOCS3 rs1061489 G > A polymorphism in controls and BC patientsModelGenotypeHealthy Controls (N = 300)N (%)BC Cases(N = 300)N (%)OR (95% CI)P-valueCodominantG/G281 (93.7%)231 (77.0%)1.00G/A17 (5.7%)64 (21.3%) 4.58 (2.61–8.04) < 0.0001A/A2 (0.6%)5 (1.7%)3.04 (0.58–15.82)0.1DominantG/G281 (93.7%)231 (77%)1.00 < 0.0001G/A-A/A19 (6.3%)69 (23%) 4.42 (2.58–7.56)RecessiveG/G-G/A298 (99.3%)295 (98.3%)1.000.25A/A2 (0.7%)5 (1.7%)2.53 (0.49–13.12)Over dominantG/G-A/A283 (94.3%)236 (78.7%)1.00< 0.0001G/A17 (5.7%)64 (21.3%) 4.51 (2.57–7.92)HWE---0.040.79 --- ---Allele frequencyGA579 (96.5)21 (3.5)526 (87.67)74 (12.33) 3.87 (2.32–6.72) < 0.0001Data are presented as number (percentage). BC Breast Cancer, OR Odds Ratio, CI Confidence Interval, HWE Hardy–Weinberg Equilibrium. P values were calculated using the chi-square (χ²) test or Fisher’s exact test, where appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression analysis. A p value < 0.05 was considered statistically significant Genotype and allele frequency distribution of SOCS3 rs1061489 G > A polymorphism in controls and BC patients G A 579 (96.5) 21 (3.5) 526 (87.67) 74 (12.33) Data are presented as number (percentage). BC Breast Cancer, OR Odds Ratio, CI Confidence Interval, HWE Hardy–Weinberg Equilibrium. P values were calculated using the chi-square (χ²) test or Fisher’s exact test, where appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression analysis. A p value < 0.05 was considered statistically significant Association analysis of genotypes and alleles with risk of BC The genotypic and allelic frequencies of the SNPs in SOCS3 gene (rs4969169 C > T, rs12953258 C > A and rs1061489 G > A) in 300 control group and 300 breast cancer patients are summarized in Table 8. The frequencies of the T-allele, CT and TT genotypes of rs4969169 C > T, the A-allele and CA genotype of rs12953258 C > A, and the A-allele and GA genotype of rs1061489 G > A showed a significant association with breast cancer risk (p < 0.01). Table 8Distribution of SOCS3 genotypes among the healthy controls and breast carcinoma patientsPolymorphismGenotype frequencyAllele frequencyp-valueSOCS3 rs4969169 C > TControls (n = 300)Cases (n = 300)CC82.067.3CT16.727.7TT1.35.0C/T90.3/19.381.1/18.8< 0.01SOCS3 rs12953258 C > AControls (n = 300)Cases (n = 300)CC85.073.3CA14.324.0AA0.72.7C/A92.1/7.885.3/14.6< 0.01SOCS3 rs1061489 G > AControls (n = 300)Cases (n = 300)GG93.777.0GA5.621.3AA0.71.7G/A96.5/3.587.6/12.3< 0.01Data are presented as percentage values. BC Breast Cancer. P values were calculated using the chi-square (χ²) test comparing genotype and allele frequency distributions between cases and controls. A p value < 0.05 was considered statistically significant. Distribution of SOCS3 genotypes among the healthy controls and breast carcinoma patients SOCS3 rs4969169 C > T Controls (n = 300) Cases (n = 300) CC 82.0 67.3 CT 16.7 27.7 TT 1.3 5.0 C/T 90.3/19.3 81.1/18.8 SOCS3 rs12953258 C > A Controls (n = 300) Cases (n = 300) CC 85.0 73.3 CA 14.3 24.0 AA 0.7 2.7 C/A 92.1/7.8 85.3/14.6 SOCS3 rs1061489 G > A Controls (n = 300) Cases (n = 300) GG 93.7 77.0 GA 5.6 21.3 AA 0.7 1.7 G/A 96.5/3.5 87.6/12.3 Data are presented as percentage values. BC Breast Cancer. P values were calculated using the chi-square (χ²) test comparing genotype and allele frequency distributions between cases and controls. A p value < 0.05 was considered statistically significant. Genotypes association with clinicopathological characteristics of breast carcinoma Association between genotypic and clinicopathological characteristics in BC patients are summarized in Table 9. It has revealed that the most of the breast carcinoma patients with TT genotype of rs4969169 C > T and AA genotype of SOCS3 rs12953258 C > A gene polymorphisms were found in the late stage similarly, most of the patients with GA and AA genotype of rs1061489 G > A gene polymorphism were found to be in late stage of BC. The analysis of polymorphic variant rs12953258 C > A and rs1061489 G > A of SOCS3 gene revealed that AA genotypes of both polymorphisms were significantly associated with lobular carcinoma in BC patients. CT and TT genotypes of SOCS3 rs4969169 C > T; CA and AA genotypes of rs12953258 C > A polymorphism are found to be associated with ER -ve receptor status. CT and CA genotypes of SOCS3 rs4969169 C > T and rs12953258 C > A were found to be significantly associated with PR -ve and Her2/neu -ve receptor status, AA genotype of SOCS3 gene rs12953258 C > A had significant association with Her2/neu receptor status. GA genotype of SOCS3 rs1061489 G > A was found to be associated with ER-ve, PR-ve and Her2/neu -ve receptor status. Table 9Genotype frequencies of SOCS3 gene and clinicopathological features of breast carcinoma patientsCharacteristicsSOCS3 rs4969169 C > TSOCS3 rs12953258 C > ASOCS3 rs1061489 G > ACCCTTTCCCAAAGGGAAAStage of cancerEarly 197 (65.67)Late 103 (34.33)AOR (95% CI)p-value70.0562.141.0 (ref)28.4326.211.01(0.53–1.92)0.41.5211.6512.16(2.10-256.2)0.00477.1666.021.0 (ref)21.8328.161.47(0.77–2.85)0.11.015.827.87(1.07–198.2)0.0588.3255.341.0 (ref)11.1740.785.17(2.53–11.09)< 0.000010.513.881.06(1.00-1.14)0.05Type of CancerDuctal 247 (82.33)Lobular 53 (17.67)AOR (95% CI)p-value65.5975.471.0 (ref)29.1520.750.63(0.32–1.22)0.25.263.780.69(0.16–2.84)0.774.9066.041.0 (ref)23.4826.411.35(0.70–2.61)0.31.627.558.18(1.31–178.4) 0.0479.3566.041.0 (ref)20.2426.421.49(0.76–2.92)0.10.417.548.47(1.24–200.1) 0.009Axillary Lymph node statusPositive 219(73)Negative 81 (27)AOR (95% CI)p-value68.0465.431.0 (ref)28.3125.930.95(0.50–1.81)0.93.658.642.86(0.79–13.05)0.273.9771.601.0 (ref)23.2925.931.15(0.60–2.22)0.062.742.470.63(0.07–4.27)0.181.2865.431.0 (ref)17.3532.102.26(1.16–4.48) 0.011.372.471.32(0.13–13.51)0.4ER StatusPositive 177 (59)Negative 123 (41)AOR (95% CI)p-value81.9246.341.0 (ref)16.9543.094.41(2.28–8.76) < 0.0001*1.1310.5724.28(3.57–614) 0.000484.7556.911.0 (ref)14.6937.404.05(2.04–8.36) < 0.00010.564.881.10(1.00-1.18) 0.0190.9656.911.0 (ref)8.4739.847.64(3.46–18.34) < 0.00010.573.255.38(0.53–153.8)0.09PR StatusPositive 167 (55.67)Negative 133 (44.33)AOR (95% CI)p-value78.4453.381.0 (ref)17.9739.852.94 (1.54–5.74) 0.0002*3.596.771.96(0.52–7.92)0.183.8360.151.0 (ref)14.3736.093.43(1.73–7.05) 0.00021.805.693.50(0.54–32.26)0.286.8364.661.0 (ref)12.5732.333.28(1.61–6.95) 0.00050.603.016.73(0.41–109.6)0.1HER2/neu StatusPositive 163 (54.33)Negative 111 (37)AOR (95% CI)p-value73.6257.661.0 (ref)22.7035.132.15(1.14–4.11) 0.02*3.687.213.58(0.92–17.71)0.184.6658.561.0 (ref)14.7236.033.50(1.76–7.16) 0.00020.625.411.08(1.00-1.17) 0.0285.2866.671.0 (ref)13.5031.532.77(1.37–5.76) 0.0011.221.802.52(0.18–75.21)0.001Metastasis StatusPositive 102 (34)Negative 198 (66)AOR (95% CI)p-value63.7269.201.0 (ref)31.3825.750.77(0.41–1.45)0.24.905.050.92(0.23–3.62)0.464.7177.781.0 (ref)29.4121.210.58(0.30–1.12)0.085.881.010.14(0.006-1.00)0.0479.4175.761.0 (ref)19.6122.221.15(0.58–2.31)0.30.982.022.08(0.15–62.53)0.4Triple Negative Breast cancerNon-TNBC 215 (78.47)TNBC 59 (21.53)AOR (95% CI)p-value63.2681.361.0 (ref)30.7016.940.43(0.21–0.85)0.026.041.700.11(0.004–0.77)0.1373.9574.581.0 (ref)23.7222.030.91 (0.46–1.79)0.92.323.391.08 (0.17–6.90)0.979.5371.191.0 (ref)19.0727.111.75 (0.89–3.49)0.21.401.702.12 (0.16–62.33)0.7Data are presented as percentages (%). AOR Adjusted Odds Ratio, CI Confidence Interval, ER Estrogen Receptor, PR Progesterone Receptor, HER2 Human Epidermal Growth Factor Receptor 2, TNBC Triple-Negative Breast Cancer. AOR and 95% CI were obtained from multivariate logistic regression analysis. P values were calculated using chi-square (χ²) or Fisher’s exact test as appropriate. A p value < 0.05 was considered statistically significant Genotype frequencies of SOCS3 gene and clinicopathological features of breast carcinoma patients Stage of cancer Early 197 (65.67) Late 103 (34.33) AOR (95% CI) p-value 70.05 62.14 1.0 (ref) 28.43 26.21 1.01(0.53–1.92) 0.4 1.52 11.65 12.16(2.10-256.2) 0.004 77.16 66.02 1.0 (ref) 21.83 28.16 1.47(0.77–2.85) 0.1 1.01 5.82 7.87(1.07–198.2) 0.05 88.32 55.34 1.0 (ref) 11.17 40.78 5.17(2.53–11.09) < 0.00001 0.51 3.88 1.06(1.00-1.14) 0.05 Type of Cancer Ductal 247 (82.33) Lobular 53 (17.67) AOR (95% CI) p-value 65.59 75.47 1.0 (ref) 29.15 20.75 0.63(0.32–1.22) 0.2 5.26 3.78 0.69(0.16–2.84) 0.7 74.90 66.04 1.0 (ref) 23.48 26.41 1.35(0.70–2.61) 0.3 1.62 7.55 8.18(1.31–178.4) 0.04 79.35 66.04 1.0 (ref) 20.24 26.42 1.49(0.76–2.92) 0.1 0.41 7.54 8.47(1.24–200.1) 0.009 Axillary Lymph node status Positive 219(73) Negative 81 (27) AOR (95% CI) p-value 68.04 65.43 1.0 (ref) 28.31 25.93 0.95(0.50–1.81) 0.9 3.65 8.64 2.86(0.79–13.05) 0.2 73.97 71.60 1.0 (ref) 23.29 25.93 1.15(0.60–2.22) 0.06 2.74 2.47 0.63(0.07–4.27) 0.1 81.28 65.43 1.0 (ref) 17.35 32.10 2.26(1.16–4.48) 0.01 1.37 2.47 1.32(0.13–13.51) 0.4 ER Status Positive 177 (59) Negative 123 (41) AOR (95% CI) p-value 81.92 46.34 1.0 (ref) 16.95 43.09 4.41(2.28–8.76) < 0.0001* 1.13 10.57 24.28(3.57–614) 0.0004 84.75 56.91 1.0 (ref) 14.69 37.40 4.05(2.04–8.36) < 0.0001 0.56 4.88 1.10(1.00-1.18) 0.01 90.96 56.91 1.0 (ref) 8.47 39.84 7.64(3.46–18.34) < 0.0001 0.57 3.25 5.38(0.53–153.8) 0.09 PR Status Positive 167 (55.67) Negative 133 (44.33) AOR (95% CI) p-value 78.44 53.38 1.0 (ref) 17.97 39.85 2.94 (1.54–5.74) 0.0002* 3.59 6.77 1.96(0.52–7.92) 0.1 83.83 60.15 1.0 (ref) 14.37 36.09 3.43(1.73–7.05) 0.0002 1.80 5.69 3.50(0.54–32.26) 0.2 86.83 64.66 1.0 (ref) 12.57 32.33 3.28(1.61–6.95) 0.0005 0.60 3.01 6.73(0.41–109.6) 0.1 HER2/neu Status Positive 163 (54.33) Negative 111 (37) AOR (95% CI) p-value 73.62 57.66 1.0 (ref) 22.70 35.13 2.15(1.14–4.11) 0.02* 3.68 7.21 3.58(0.92–17.71) 0.1 84.66 58.56 1.0 (ref) 14.72 36.03 3.50(1.76–7.16) 0.0002 0.62 5.41 1.08(1.00-1.17) 0.02 85.28 66.67 1.0 (ref) 13.50 31.53 2.77(1.37–5.76) 0.001 1.22 1.80 2.52(0.18–75.21) 0.001 Metastasis Status Positive 102 (34) Negative 198 (66) AOR (95% CI) p-value 63.72 69.20 1.0 (ref) 31.38 25.75 0.77(0.41–1.45) 0.2 4.90 5.05 0.92(0.23–3.62) 0.4 64.71 77.78 1.0 (ref) 29.41 21.21 0.58(0.30–1.12) 0.08 5.88 1.01 0.14(0.006-1.00) 0.04 79.41 75.76 1.0 (ref) 19.61 22.22 1.15(0.58–2.31) 0.3 0.98 2.02 2.08(0.15–62.53) 0.4 Triple Negative Breast cancer Non-TNBC 215 (78.47) TNBC 59 (21.53) AOR (95% CI) p-value 63.26 81.36 1.0 (ref) 30.70 16.94 0.43(0.21–0.85) 0.02 6.04 1.70 0.11(0.004–0.77) 0.13 73.95 74.58 1.0 (ref) 23.72 22.03 0.91 (0.46–1.79) 0.9 2.32 3.39 1.08 (0.17–6.90) 0.9 79.53 71.19 1.0 (ref) 19.07 27.11 1.75 (0.89–3.49) 0.2 1.40 1.70 2.12 (0.16–62.33) 0.7 Data are presented as percentages (%). AOR Adjusted Odds Ratio, CI Confidence Interval, ER Estrogen Receptor, PR Progesterone Receptor, HER2 Human Epidermal Growth Factor Receptor 2, TNBC Triple-Negative Breast Cancer. AOR and 95% CI were obtained from multivariate logistic regression analysis. P values were calculated using chi-square (χ²) or Fisher’s exact test as appropriate. A p value < 0.05 was considered statistically significant HapMap analysis HapMap analysis of different ethnic groups We compared allele frequencies of SOCS3 gene in different ethnic groups (African, East Asian, Europe and South Asian) using HapMap dataset, the frequency of alleles of rs4969169 C > T and rs12953258 C > A to be similar with allele frequencies in HapMap populations to that of our population depicted in Fig. S1. There was no previous data available for rs1061489 G > A polymorphism for conducting HapMap studies and we are reporting this for the first time. Haplotype analysis The most likely common haplotypes of the three SOCS3 gene polymorphisms are tabulated in Table 10. Out of the 7 haplotypes (C-C-G (ref), T-C-G, C-A-G, C-C-A, T-A-G, T-C-A and C-A-A), T-C-G, C-A-G, C-C-A and T-C-A haplotypes of SOCS3 rs4969169 C > T, rs12953258 C > A and rs1061489 G > A SNPs were found to be associated with 2.18 (95%CI: 1.45–3.27;p = 0.0002), 2.64 (95%CI: 1.61–4.33; p = 0.0001), 3.65 (95%CI: 1.85–7.20; p = 0.0002) and 13.66 (95%CI:2.10-89.05; p = 0.006) folds risk respectively for development of Breast cancer. Table 10Frequencies of SOCS3 haplotypes (rs4969169 C > T, rs12953258 C > A, rs1061489 G > A) in BC patients and healthy controlsHaplotypeControlsCasesCumulativefrequencyOR (95% CI)P-valueCCG0.82020.60910.72031.00---TCG0.07440.13880.8222.18 (1.45–3.27)0.0002CAG0.05150.11050.89922.64 (1.61–4.33)0.0001CCA0.0240.07420.94553.65 (1.85–7.20)0.0002TAG0.01890.01830.96721.65 (0.58–4.68)0.35TCA0.00320.03120.986313.66 (2.10–89.05)0.0065CAA0.00770.017913.21 (0.92–11.17)0.067The table summarizes the distribution of common haplotypes and their association with breast cancer risk. Odds ratios (OR) and 95% confidence intervals (CI) were calculated with the CCG haplotype as the reference. Statistically significant associations (p < 0.05) Frequencies of SOCS3 haplotypes (rs4969169 C > T, rs12953258 C > A, rs1061489 G > A) in BC patients and healthy controls The table summarizes the distribution of common haplotypes and their association with breast cancer risk. Odds ratios (OR) and 95% confidence intervals (CI) were calculated with the CCG haplotype as the reference. Statistically significant associations (p < 0.05) Analysis of clinicopathological variables with haplotypes revealed that C-A-G and C-C-A haplotypes are associated with histological type of BC. In addition, the C-C-A haplotype correlated with axillary lymph node status and C-A-G haplotype was associated with metastasis status of BC, as summarized in Table 11. Table 11Association of SOCS3 haplotypes (rs4969169 C > T, rs12953258 C > A and rs1061489 G > A) with clinicopathological variables of BC patientsClinicopathological VariablesHaplotypeVariable presenceOR (95%CI)P-valueStage of the cancerCAGCCAEarly stage0.09830.0676Late stage0.13510.09271.39 (0.72–2.66)1.37 (0.65–2.90)0.320.41Type of cancerCAGCCADuctal0.09820.0569Lobular0.16380.1472.11 (1.05–4.25)3.24 (1.49–7.06)0.0370.0033Axillary Lymph node StatusCAGCCA Positive0.11080.0603 Negative0.10080.11570.99 (0.48–2.03) 2.17 (1.01–4.63)0.98 0.047ER StatusCAGCCA Positive0.1250.0555 Negative0.09260.09730.71 (0.36–1.41)1.69 (0.81–3.49)0.330.16PR StatusCAGCCA Positive0.11930.0541 Negative0.10440.10030.86 (0.48–1.54)1.83 (0.88–3.80)0.60.11HER2/neu StatusCAGCCA Positive0.11110.0475 Negative0.10820.09660.94 (0.48–1.84)1.97 (0.84–4.65)0.850.12Metastasis StatusCAGCCA Positive0.15740.049 Negative0.08590.08592.01 (1.08–3.76)0.65 (0.27–1.55) 0.0290.33TNBC StatusCAGCCA Non-TNBC0.11290.0528 TNBC0.09460.10990.75 (0.33–1.69)1.93 (0.85–4.37)0.490.11*Significant at p < 0.05. ‘Variable Presence’ indicates the proportion of BC patients within each subgroup carrying the respective haplotype. Haplotype selection (CAG, CCA) was based on their higher frequency and potential functional relevance Association of SOCS3 haplotypes (rs4969169 C > T, rs12953258 C > A and rs1061489 G > A) with clinicopathological variables of BC patients CAG CCA Early stage 0.0983 0.0676 Late stage 0.1351 0.0927 1.39 (0.72–2.66) 1.37 (0.65–2.90) 0.32 0.41 CAG CCA Ductal 0.0982 0.0569 Lobular 0.1638 0.147 2.11 (1.05–4.25) 3.24 (1.49–7.06) 0.037 0.0033 CAG CCA Positive 0.1108 0.0603 Negative 0.1008 0.1157 0.99 (0.48–2.03) 2.17 (1.01–4.63) 0.98 0.047 CAG CCA Positive 0.125 0.0555 Negative 0.0926 0.0973 0.71 (0.36–1.41) 1.69 (0.81–3.49) 0.33 0.16 CAG CCA Positive 0.1193 0.0541 Negative 0.1044 0.1003 0.86 (0.48–1.54) 1.83 (0.88–3.80) 0.6 0.11 CAG CCA Positive 0.1111 0.0475 Negative 0.1082 0.0966 0.94 (0.48–1.84) 1.97 (0.84–4.65) 0.85 0.12 CAG CCA Positive 0.1574 0.049 Negative 0.0859 0.0859 2.01 (1.08–3.76) 0.65 (0.27–1.55) 0.029 0.33 CAG CCA Non-TNBC 0.1129 0.0528 TNBC 0.0946 0.1099 0.75 (0.33–1.69) 1.93 (0.85–4.37) 0.49 0.11 *Significant at p < 0.05. ‘Variable Presence’ indicates the proportion of BC patients within each subgroup carrying the respective haplotype. Haplotype selection (CAG, CCA) was based on their higher frequency and potential functional relevance In silico analyses Pre-mRNA secondary structures Pre-mRNA secondary structures of SOCS3 rs4969169 C > T polymorphism were predicted using ViennaRNA web server and the results were depicted in Figure S2. The C allele exhibited a minimum free energy (MFE) of -191.60 kcal/mol, while the T allele had an MFE of -194.30 kcal/mol. The small difference in MFE between the two alleles suggest that their structural stability is likely comparable. mRNA secondary structures The mRNA secondary structures of SOCS3 rs4969169 C > T were predicted using the RNAsnp webserver. In Figures S3.b and S3.c, the upper and lower triangles represent base-pairing probabilities for the wild-type (green) and variant (red) sequences, respectively, with the SNP location highlighted in yellow and indicated by an arrow. The maximum base pairing distance was 0.01 with a p-value of 0.72 (Figure S3), indicating that this polymorphism does not significantly affect mRNA structure. Transcription factors binding Since a significant association of the polymorphism was observed in breast cancer cases, we performed in silico analysis to further investigate the potential functional significance. In the present study, transcription factor binding sites at the polymorphic locus were identified using AliBaba2.1 tool. The results indicated that the SOCS3 rs12953258 C > A polymorphism with the C-allele (Major) contains binding sites for Sp1and AP-2alph transcription factors, whereas the A-allele (Minor) has binding sites for Sp1 and NF-1 transcription factors. This differential binding of transcription factors at the promoter region of the SOCS3 rs12953258 C > A polymorphism might alter the transcriptional activity of the gene as illustrated in Fig. 4. Transcription factors binding to promoter region of SOCS3 rs12953258 C > A polymorphism Pre-mRNA secondary structures Pre-mRNA secondary structures of SOCS3 rs1061489 G > A were predicted using the ViennaRNA web server (Figure S4). The G allele exhibited a minimum free energy (MFE) of -83.80 kcal/mol, while the A allele had an MFE of -83.00 kcal/mol. The slight difference in MFE suggests that the G allele is marginally more stable than the A allele, and a clear structural variation between the two alleles was observed. mRNA secondary structures The mRNA secondary structures of SOCS3 rs1061489 G > A were predicted using RNAsnp webserver. In Figures S5.b and S5.c, the upper and lower triangles represent base-pairing probabilities for the wild-type (green) and variant (red) sequences, respectively, with the SNP location highlighted in yellow and indicated by an arrow. The maximum base-pairing distance for this SNP was 0.01, with a p-value of 0.77 (Figure S5), indicating that the rs1061489 G > A polymorphism does not significantly affect mRNA structure. Discussion Breast cancer is the most frequently diagnosed malignancy among women worldwide [20]. The risk of developing breast cancer is multifactorial [21] influenced by a complex interplay of genetic, epigenetic, environmental, and lifestyle factors, which are closely associated with specific tumor subtypes categorized by hormone receptor status and other characteristics in breast cancer. Growing evidence indicates that single nucleotide polymorphisms in various genes are known to influence the transcriptional activity and consequently alter gene expression, thereby contributing to breast cancer susceptibility and progression [22–24]. To the best of our knowledge, this is the first study to investigate SOCS3 gene polymorphisms in breast cancer. The present study aims to evaluate the association of SOCS3 (rs4969169 C>T, rs12953258 C > A and rs1061489 G>A) polymorphisms with epidemiological and clinicopathological characteristics in patients with breast cancer. Previous studies have reported no significant association between the SOCS3 rs4969169 C >T polymorphism and diseases such as Graves ophthalmopathy, body weight, insulin sensitivity or lipid profile [25, 26]. In contrast, our findings demonstrated that both the TT genotype and T allele frequencies of SOCS3 rs4969169 C>T were higher among breast cancer patients than in healthy conferring approximately 4.29 and 2.16 folds increased risk respectively. These results suggest that this variant may play a contributory role in breast cancer susceptibility, possibly through its regulatory influence on cytokine signaling pathways. The SOCS3 rs12953258 C>A polymorphism has previously been implicated in increased susceptibility to hepatitis B virus (HBV) infection and the progression of HBV-related liver diseases [27] as well as in Type 1 diabetes [28]. However, no significant associations were observed with hepatocellular carcinoma, colorectal cancer, and Dyslipidemia [29–31]. In the present study, the CA genotype and A allele frequencies of SOCS3 rs12953258 C >A were higher in breast cancer patients than in controls, conferring 1.95 and 2.02 folds increased risk respectively This finding indicates that the rs12953258 variant may contribute to breast cancer development through mechanisms distinct from those observed in other malignancies. To the best of our knowledge, this is the first study to investigate the SOCS3 rs1061489 G > A polymorphism in breast cancer. Our results revealed that the GA genotype and A allele were more frequent in breast cancer patients, conferring approximately 4.58- and 3.87-fold increased risks, respectively. Given the established role of SOCS3 as a negative regulator of the JAK/STAT signaling pathway, these findings suggest that genetic variations in SOCS3 may alter its expression or function, thereby contributing to dysregulated cytokine signaling and breast tumorigenesis. SOCS3 gene polymorphisms (rs4969169 C>T, rs12953258 C > A and rs1061489 G>A) were analyzed in relation to clinicopathological parameters, significant associations were observed with several markers of breast carcinoma progression and susceptibility the TT genotype of SOCS3 rs4969169 C > T and the AA genotype of rs12953258 C > A and rs1061489 G > A were significantly associated with late stage and ER-ve status. Additionally, the AA genotype of rs12953258 C > A and rs1061489 G > A revealed a significant association with histological subtype (lobular carcinoma) of BC. Further AA genotype of rs12953258 C > A and rs1061489 G > A revealed a significant association with Her2/neu -ve receptor status. The GA genotype of rs1061489 G>A was found to be significantly associated with the lymph node status and PR-ve receptor status. Collectively, these findings suggest that SOCS3 polymorphisms may influence key clinicopathological characteristics associated with breast cancer aggressiveness. Moreover, identifying genetic variations in the form of haplotypes rather than individual single-nucleotide polymorphisms (SNPs) may offer a more comprehensive understanding of genetic predisposition and serve as a promising approach for elucidating the molecular basis of breast cancer susceptibility [20]. From a biological perspective, SOCS3 is a critical negative regulator of the JAK/STAT signaling pathway, which plays a central role in cell proliferation, differentiation, and apoptosis. Altered SOCS3 expression or function due to genetic polymorphisms may lead to dysregulated cytokine signaling, promoting tumor cell survival, immune evasion, and angiogenesis. In breast cancer, loss or suppression of SOCS3 expression has been linked to enhanced STAT3 activation and increased tumor aggressiveness [32]. Therefore, the observed associations of specific SOCS3 variants with ER-negative, PR-negative, and HER2/neu-negative subtypes may reflect the gene’s involvement in modulating oncogenic signaling pathways that drive tumor progression and poor prognosis. Haplotype analysis of SOCS3 gene polymorphisms revealed a significant association with breast cancer (BC) development. Specifically, the T-C-G, C-A-G, C-C-A, and T-C-A haplotypes were associated with an increased risk of BC by 2.18-fold, 2.64-fold, 3.65-fold, and 13.66-fold, respectively. Notably, the haplotype comprising the risk alleles (T allele of rs4969169 C > T, A allele of rs12953258 C > A, and A allele of rs1061489 G > A) conferred a markedly higher susceptibility to breast carcinoma. These findings are consistent with the results obtained from individual SNP analyses, reinforcing the potential role of SOCS3 genetic variations in BC progression. The analysis of SOCS3 gene polymorphisms (rs4969169 C > T, rs12953258 C > A, and rs1061489 G > A) and their haplotypes in relation to clinicopathological parameters demonstrated significant associations with key features of breast cancer progression. Specifically, the C-A-G and C-C-A haplotypes were significantly correlated with the histological subtype of breast carcinoma, suggesting a possible influence of these genetic variants on tumor differentiation and pathological behavior. Moreover, the C-C-A haplotype showed a significant association with axillary lymph node involvement, while the C-A-G haplotype was linked to metastatic status, indicating their potential roles in tumor invasiveness and dissemination. These findings highlight the functional importance of SOCS3 haplotypes in modulating tumor aggressiveness and progression, aligning with the gene’s known role as a negative regulator of cytokine signaling and tumor suppressor in various malignancies. Further to the haplotype analysis, we examined the allele frequency distribution of SOCS3 polymorphisms (rs4969169 C > T, rs12953258 C > A, and rs1061489 G > A) across diverse populations, including South Asian, European, East Asian, and African cohorts, using HapMap data, along with the Indian population. The analysis revealed that the T allele of rs4969169 C > T, A allele of rs12953258 C > A, and A allele of rs1061489 G > A were significantly associated with an increased risk of breast cancer, suggesting population-level differences in genetic predisposition. These allelic variants may alter SOCS3 expression or functional activity, thereby influencing cytokine-mediated oncogenic signaling pathways. To the best of our knowledge, the current study is the first to report a significant association of SOCS3 gene polymorphisms (rs4969169 C > T, rs12953258 C > A, and rs1061489 G > A) and their haplotypes (T-C-G, C-A-G, C-C-A, and T-C-A) with breast cancer susceptibility and clinicopathological features. The integrative evaluation of single SNPs, haplotypes, and clinicopathological correlations provides comprehensive insight into the potential contribution of SOCS3 genetic variants to the molecular pathology of breast carcinoma. These findings collectively underscore the potential of SOCS3 polymorphisms and haplotypes as promising biomarkers for breast cancer risk stratification and progression, and warrant further validation in larger, ethnically diverse cohorts. Overall, our findings reveal that polymorphisms in the SOCS3 gene rs4969169 C > T, rs12953258 C > A and rs1061489 G > A when correlated with clinicopathological characteristics was found to be having significant effects on the risk and progression of breast cancer. Insilco analyses further provide predictive and statistically supportive evidence suggesting potential regulatory effects of these variants on SOCS3 gene expression and function, which warrant future mechanistic validation. Conclusion The present study focused on elucidating the clinical significance of single nucleotide polymorphisms in the SOCS3 gene in relation to breast cancer progression, with the broader aim of identifying individuals at increased risk of developing the disease. Such a comprehensive approach may aid in the identification of prominent candidate molecular markers for the diagnosis and prognosis of breast carcinoma. Furthermore, gaining deeper insights into the molecular mechanisms and signaling pathways regulating SOCS3 gene expression across different breast cancer subtypes is crucial for the development of novel therapeutic strategies and preventive interventions. Limitations of the study This is the first study reporting on the SNPs of SOCS3 gene in Breast Cancer in correlation with clinicopathological variables and Insilco analysis. However, the study has some limitations. Although the findings are statistically robust, several limitations should be acknowledged: Single-population cohort: Results are specific to South Indian women and may not be generalizable to other ethnic groups. Therefore, further collaborative research studies on different populations with a larger sample size are required to corroborate our study findings. Limited environmental data: Information on hormonal contraceptive use, diet, and chemotherapy history was incomplete for some participants. Lack of functional validation: Experimental studies are needed to confirm how these variants affect SOCS3 expression in breast tissue. Sample size for TNBC subgroup: TNBC-specific studies would further validate these associations. Although PCR-RFLP and ARMS-PCR are classical genotyping methods, they remain robust and reproducible when optimized appropriately. In the present study, stringent quality control measures were applied to ensure accuracy, including repeat genotyping and inclusion of control samples. Nonetheless, future work incorporating direct sequencing validation is warranted to confirm the observed associations. Future investigations should include multi-centric replication, transcriptomic validation, and gene–environment interaction analyses to confirm the biological implications of SOCS3 polymorphisms in breast carcinogenesis. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Acknowledgments Clinical trial number Not applicable. Authors’ contributions Raviteja Reddy Alipeddi: Collection of blood samples, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. Chiranjeevi Padala, Kaushik Puranam & Kayalvili Ulaganathan: Formal analysis, Validation, Writing – review & editing. Rani Durga Neeharika & Pallavi Sampanmudumby : Writing – review & editing. Sanjeeva Kumari Chinta: Provision of BC patients, blood samples, Data curation, Investigation, Resources, Validation, Writing – review & editing. Surekha Rani Hanumanth*- Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Funding information Department of Science and Technology, Ministry of Science and Technology, India. (DST/INSPIRE Fellowship/[IF190644]) Department of Biotechnology, Ministry of Science and Technology, India (BT/INF/22/SP41415/2021). Data availability All data supporting the findings of this study are available within the paper. Primer sequences are provided in Table 1. insilico results are provided as separate supplementary document. Declarations Ethics approval and consent to participate The study was approved by the Ethics Committee (Institute of Genetics and Hospital for Genetic Disorders), Begumpet Hyderabad, India: Approval number 10/EC/NEW/INST/2023/4032 dated: 22/12/2023). Written informed consent was duly obtained from all subjects. Institutional Ethical Committee approval was obtained prior to the commencement of study and was in compliance with the Helsinki Declaration. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Data Availability Statement All data supporting the findings of this study are available within the paper. Primer sequences are provided in Table 1. insilico results are provided as separate supplementary document.